After many years of success, EvidenceNetwork.ca is no longer in operation. We would like to thank everyone who has contributed to the organization over the past decade including our dedicated researchers, newspaper editors, readers and funders. However, now it is time to move onto new ways of looking at knowledge mobilization and policy. Should you have any questions, please feel free to contact Shannon Sampert at s.sampert@uwinnipeg.ca.

Purdue Pharma given free reign in Canada as it is sanctioned in the United States

Opioid manufacturer admits to illegal activity in the United States but faces no penalties in Canada   Purdue Pharma recently announced that it will stop advertising opioids to doctors in the United States after pleading guilty to misleading marketing more than a decade ago. This is a major, albeit belated, departure from the company’s playbook […]

From prescriptions to prevention: Managing Canada’s opioid addiction

Canada has an opioid problem and it’s more widespread than fentanyl on our streets:  We are becoming increasingly dependent on doctor-prescribed opioids. Drs. Kate Smolina and Kim Rutherford explain why and how to kick our prescription opioid habit. Kate Smolina is an expert advisor with EvidenceNetwork.ca.  She was a postdoctoral fellow at the School of Population […]